<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Column of Key Laboratory of National Medical Products Administration]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Constructing digitally-oriented TCM quality standard system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To construct digitally-oriented TCM quality standard system to provide possible strategies for solving the current problems of TCM quality standard system.<b>Methods</b>  Combined with the routine work of TCM control, the status quo and problems of TCM quality standard system were analysed, and the corresponding countermeasures were put forward, through literature review, market research, and discussion with relevant experts and scholars and personnel of TCM manufacturers. <b>Results</b>  At present, there are some problems in the TCM quality standard, such as lagging standards, lack of overall quality evaluation methods, deviation from the support of TCM theory and clinical practice, poor process controllability, and insufficient specificity of quality control indexes. And there are also many problems in the management and implementation of TCM quality standard in China, such as many kinds of classification, difficult query, multiple standards of one variety, traditional character identification being susceptible to subjective and objective factors, and poor accessibility of physical standard substances. Based on this, it is suggested to establish and improve the unified and authoritative TCM quality standard information inquiry platform and TCM digital herbarium, and to devote to the research of TCM quality standard based on digitalization. <b>Conclusion</b>  The construction of digitally-oriented TCM quality standard system will contribute to the improvement of TCM quality and the scientific formulation of TCM standard, and could solve various problems existing in the management and implementation of TCM quality standard.]]></description>
<pubDate>2022/9/5 13:24:44</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[LUAN Yongfu, GUO Dongxiao, WANG Bing, XIE Yingying, ZHOU Guangtao, LIN Yongqiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LUAN Yongfu, GUO Dongxiao, WANG Bing, XIE Yingying, ZHOU Guangtao, LIN Yongqiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208006&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Detection of Adulterated <i>Ginseng Radix</i> ET Rhizoma in Naolingsu Preparations by HPLC-MS/MS]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a method for the detection of adulterated <i>Ginseng Radix</i> ET Rhizoma in Naolingsu Preparations.<b>Methods</b>  An HPLC-MS/MS in MRM mode was adopted. The Agilent ZORBAX Eclipse Plus C<sub>18</sub> column（2.1 mm×100 mm, 1.8 µm）was used with acetonitrile-water as the mobile phase. The flow rate was 0.35 mL·min<sup>-1</sup>, the column temperature was 40 ℃,and the injection volume was 5 µL.<b>Results</b>  In the 66 batches of samples of Naolingsu Preparations 36 batches of samples were adulterated with Panacis Quinquefolii Radix ,the detectable rate was 54.4%. <b>Conclusion</b>  There were adulterated <i>Ginseng Radix</i> ET Rhizoma in Naolingsu Preparations. The method is accurate and reliable, which can provide reference for the quality control of <i>Ginseng Radix</i> ET Rhizoma in Naolingsu Preparations.]]></description>
<pubDate>2022/9/5 13:24:44</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[MU Xiangrong<sup>1</sup>, XU Xingyan<sup>1</sup>, JIAO Yang<sup>1</sup>, XU Lili<sup>1,2</sup>, YIN Xue<sup>1</sup>, LIN Yongqiang<sup>1</sup>, LIN Huibin<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MU Xiangrong<sup>1</sup>, XU Xingyan<sup>1</sup>, JIAO Yang<sup>1</sup>, XU Lili<sup>1,2</sup>, YIN Xue<sup>1</sup>, LIN Yongqiang<sup>1</sup>, LIN Huibin<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202208007&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on titer prediction of erythromycin enteric coated tablets based on GA-BP artificial neural network]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a GA-BP artificial neural network model to predict the titer of erythromycin enteric coated tablets according to the component content data.<b>Methods</b>  The contents and potency of erythromycin component A, erythromycin component B, erythromycin component C, impurity A-F and total impurities in 552 batches of erythromycin enteric coated tablets were determined, and the GA-BP artificial neural network model was constructed to predict the potency of erythromycin enteric coated tablets.<b>Results</b>   The highest error percentage of predicted titer was - 4.61%, which was not more than 5%. The average error percentage was 2.22%, which was better than the relative standard deviation of general instrumental analysis by 2.50%. <b>Conclusion</b>  GA-BP artificial neural network has high accuracy and stability in predicting the titer of erythromycin enteric coated tablets, and can be used for the quality control of erythromycin.]]></description>
<pubDate>2022/6/8 14:30:15</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[WU Jianzhuo, PENG Jie, WANG Tingting, LI Xue]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Jianzhuo, PENG Jie, WANG Tingting, LI Xue</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205007&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Thoughts on the Establishment of Comprehensive Service platform for Biopharmaceutical Industry in Shandong Province based on Field investigation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Based on the current situation of the development of biomedical industry in Shandong Province, put forward the trend and demand of building a comprehensive biomedical service platform through field investigation. By analyzing the common problems of existing service institutions, exploring the innovative development needs and bottlenecks of industry, university and research, this paper puts forward some ideas on the establishment model, system construction, talent introduction, cultivation and development, in order to provide ideas for the construction of innovative service ecosystem.]]></description>
<pubDate>2022/5/10 10:37:36</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[WEI Xia, HU Defu, ZHU Qingfen, SHI Feng, YU Yongmei, CUI Yuhua, LI Jun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Xia, HU Defu, ZHU Qingfen, SHI Feng, YU Yongmei, CUI Yuhua, LI Jun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204006&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on emulsifying properties and critical quality attributes of emulsifiers]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Emulsifier is a kind of surfactant widely used in drugs. Most of them are composed of protein, phospholipid, polysaccharide, amphiphilic synthetic substances or complexes of these substances. The types, characteristics and applications of emulsion preparations were reviewed through sorting and retrieving literature. The paper expounded the physical and chemical properties, emulsifying characteristics of several different types of emulsifiers such as lecithin, protein, polysaccharide, Tweens and Spans, and introduced the research on the key material properties or functional related indexes of emulsifiers, At the same time, the future research hotspots and directions of emulsifier were prospected.]]></description>
<pubDate>2022/5/10 10:37:36</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[QIN Yun, TU Jiasheng, SUN Chunmeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIN Yun, TU Jiasheng, SUN Chunmeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204007&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of Clopidogrel Injections]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Patients suffering acute coronary syndrome (ACS) usually need to receive percutaneous coronary intervention (PCI). Clopidogrel is generally given to patients before operation to exert antiplatelet function. However, there is only clopidogrel tablet in the market at present, and the onset time is too long so that it is easy to miss the optimum therapeutic time. Therefore, it is urgent to develop an injectable clopidogrel formulation for clinical application. Once marketed, it can not only provide a more flexible and effective option for patients with ACS, but also improve the success rate of emergency PCI and reduce the incidence of thrombosis and the risk of death. In this review, we will introduce the progress of clopidogrel injections, briefly discuss their technical features, and provide references for the research and development of clopidogrel injections.]]></description>
<pubDate>2022/2/23 16:42:51</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[WANG Xueyi, SUN Pingping, SUN Chunmeng, TU Jiasheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xueyi, SUN Pingping, SUN Chunmeng, TU Jiasheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201007&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the relationship between material attributes and lubrication performance of Magnesium stearate and flavor]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Lubricant is a kind of pharmaceutical excipients commonly used in oral solid preparations, which can effectively improve material fluidity and reduce material and mechanical friction coefficient. However, due to the differences in raw materials, processes and quality control requirements used by different manufacturers, it may lead to the situation that "although the common name of lubricants is the same, the properties of lubricants from different sources are not the same", thereby leading to differences in lubrication performance. In this study, Magnesium stearate (MgSt) and flavors from different manufacturers were collected. The powder properties such as bulk density, vibration density, particle size distribution, specific surface area, and the thermodynamic properties such as glass transition temperature and melting point were investigated. The critical material attributes that affect the lubrication performance are clarified, which provides a reference for the quality control and the functionality-related characteristics of related lubricants.]]></description>
<pubDate>2023/1/17 13:57:58</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[ZHENG Zhiyuan, LIU Zhengyu, HE Dongsheng, SUN Chunmeng, TU Jiasheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Zhiyuan, LIU Zhengyu, HE Dongsheng, SUN Chunmeng, TU Jiasheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212006&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Determination of lovastatin and lovastatin acid in Hongqu rice by relative correction factor]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>To establish the relative correction factor for the content of two lovastatins in the Hongqu rice.<b>Methods</b> Lovastatin was used as an indicator, and to establish the relative between the lovastatin and the lovastatin acid. The relative correction factor was used to calculate the amount of lovastatin acid. At the same time，the accuracy of the relative correction factor was evaluated by comparing the contents of lovastatin acid with those obtained by the external standard method and to evaluate the accuracy and scientificity of the relative correction factor in the Hongqu rice．<b>Results</b>There is no significant difference between the relative correction factor and the measured values of external standard in the total amount of lovastatin and lovastatin acid of the 17 batches of red rice.<b>Conclusions</b>The relative correction factor can be used to control the amount of two components and this study provided a reference for the quality evaluation model of multi-index components of traditional Chinese medicine.]]></description>
<pubDate>2023/4/21 10:23:01</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[XIE Yingying<sup>1</sup>, WANG Bing<sup>1</sup>, LUAN Yongfu<sup>1</sup>, LIN Yongqiang<sup>1</sup>, GUO Hongmei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Yingying<sup>1</sup>, WANG Bing<sup>1</sup>, LUAN Yongfu<sup>1</sup>, LIN Yongqiang<sup>1</sup>, GUO Hongmei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302007&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Test of triglochinic acid in Naoliqing preparations by ultra high performance liquid chromatography-triple quadrupole mass spectrometry]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish an analysis method for the determination of triglochinic acid in Naoliqing preparations.<b>Methods</b>  After extracted and enriched ,the samples were analyzed using ultra high performance liquid chromatography-triple quadrupole mass spectrometry(UPLC-MS/MS),and the adulterant of <i>Pinelliae Pedatisectae Rhizoma</i> in Naoliqing preparations was monitored by using triglochinic acid as index component.The samples were separated by Waters ACQUITY UPLC HSS T3 C<sub>18</sub> column(2.1 mm×100 mm,1.8 µm),eluted by gradient with acetonitrile-0.1%formic acid solution as mobile phase ,with flow rate of 0.2 mL/min; column temperature of 30 ℃,injection volume of 2 µL;Electrospray ionization source was used negative ion mode and multiple reaction monitoring(MRM) mode was performed with transitions of m/z187→143 and m/z187→99. <b>Results</b>  88 batches of Naoliqing preparations were detected by the established method, triglochinic acid were found in 15 batches of samples from 5 manufactures.<b>Conclusion</b>  The proposed method method was specific,precise,reliable,and suitable for identification of triglochinic acid in Naoliqing preparations；At the same time,it also provides a reference for the monitoring of <i>Pinelliae Rhizoma</i> adulterated with <i>Pinelliae Pedatisectae Rhizoma</i> in preparations.]]></description>
<pubDate>2023/4/21 10:23:02</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[YU Fengrui<sup>1</sup>, QIAN Limin<sup>2</sup>, YIN Xue<sup>1</sup>, JIAO Yang<sup>1</sup>, XU Xingyan<sup>1</sup>, LIN Yongqiang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Fengrui<sup>1</sup>, QIAN Limin<sup>2</sup>, YIN Xue<sup>1</sup>, JIAO Yang<sup>1</sup>, XU Xingyan<sup>1</sup>, LIN Yongqiang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302008&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Identification of <i>Cirsium japonicum</i> and <i>Cirsium setosum</i> based on mid infrared technology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To realize the classification and identification of <i>Cirsium japonicum</i> and <i>Cirsium setosum</i> based on mid infrared spectroscopy and chemometrics.<b>Methods</b> Samples of <i>Cirsium japonicum</i> and <i>Cirsium setosum</i> from different regions were collected, and the mid infrared spectrum data were collected by tablet pressing method. The mid infrared fingerprints of <i>Cirsium japonicum</i> and <i>Cirsium setosum</i> were established,and the chromatographic peaks were analyzed by TQ analysis software; Principal Component Analysis and Partial Least Squares Discriminant Analysis with SIMCA Software. <b>Results</b> The trend of the fingerprint and the position of the main absorption peak of <i>Cirsium japonicum</i> and <i>Cirsium setosum</i> were basically the same. The PCA-MD discrimination model and OPLS model established could distinguish <i>Cirsium japonicum</i> and <i>Cirsium setosum</i>. <b>Conclusion</b> <i>Cirsium japonicum</i> and <i>Cirsium setosum</i> can be distinguished by intermediate infrared spectroscopy and stoichiometry.]]></description>
<pubDate>2023/2/27 10:11:23</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[ZHANG Shihua<sup>1</sup>, GUO Chaohui<sup>2</sup>, NI Lin<sup>2</sup>, SONG Pingshun<sup>2</sup>, LI Chenquan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Shihua<sup>1</sup>, GUO Chaohui<sup>2</sup>, NI Lin<sup>2</sup>, SONG Pingshun<sup>2</sup>, LI Chenquan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301006&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress based on the development of <i>Polygonati rhizoma</i> products and resource]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Polygonati rhizoma</i> (PR) is a herbaceous plant of <i>Polygonatum</i> in Liliaceae, which has a long application history in China. PR is a traditional Chinese herbal medicine, with high value in the development of medicine and health food. This paper summarized the herbal textual research and use history of PR, compared the ancient processing with the modern processing methods, summarized the traditional efficacy and modern pharmacology, analyzed the PR resources and their sustainable utilization. The research direction and application prospect of PR were prospected in order to provide reference for the in-depth development and rational utilization of PR. Moreover, this paper can provide theoretical support for the inheritance and development of traditional Chinese medicine industry.]]></description>
<pubDate>2023/2/27 10:11:23</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[WANG Xiaobing<sup>1,2</sup>, JIANG Yaqi<sup>1</sup>, DONG Peng<sup>1</sup>, LI Qiyan<sup>1</sup>, GONG Weihong<sup>1</sup>, ZHENG Jing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xiaobing<sup>1,2</sup>, JIANG Yaqi<sup>1</sup>, DONG Peng<sup>1</sup>, LI Qiyan<sup>1</sup>, GONG Weihong<sup>1</sup>, ZHENG Jing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301007&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the potency of mRNA COVID-19 vaccine in vivo using neutralizing antibody assay]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the potency of mRNA COVID-19  vaccine in vivo by neutralizing antibody assay after  mice immunization, and establish a method to evaluate the efficacy of the vaccine.<b>Methods</b>  BALB/c mice at 6~8 weeks were immunized with mRNA COVID-19 vaccine and the neutralizing antibody titers of different immune dosage and different vaccination schedules were detected. The variant  vaccines produced by different manufactures were immunized at intervals of 7 d or 14 d, and Serum samples was collected at 7 d after the second  dose of immunization. 2019 novel coronavirus (2019-nCoV) neutralizing antibody titer and IgG antibody titer were detected by pseudo virus neutralization test and enzyme linked immunosorbent assay separately. <b>Results</b>  The results of neutralizing antibody at different immune dosage of 2 µg, 5 µg, 10 µg mRNA vaccine showed that the seropositive rate of antibody in mice was 100% and the neutralizing antibody reaction had an obvious dose-effect correlation. The neutralization antibody titer of the 14-day interval group was significantly higher than that of the 7-day interval group and one dose group (<i>F</i>=57.13, <i>P</i><0.001). The geometric mean titers (GMT) of neutralizing antibody induced by 2µg dosage interval of 7-day and 14-day were 218 and 468,respectively, with significant difference (<i>t</i>=3.40, <i>P</i>=0.003);The GMT of neutralizing antibody induced by 5 µg dosage interval of 7-day and 14-day were 499 and 1 436,respectively, with significant difference (<i>t</i>=3.62, <i>P</i>=0.002); The GMT of neutralizing antibodies induced by 10 µg dosage interval of 7-day and 14-day were 608 and 1 909 respectively, with significant difference (<i>t</i>=3.23, <i>P</i>=0.005). High levels of IgG antibody(104.5～107.5) and neutralizing antibody (102.6～104.8)could be detected after immunizing mice with the COVID-19 mRNA vaccine, potency of the vaccines were all met with the requirements with good lot consistence, there were significant difference in the antibody titers among the various vaccine produced by different manufacturers (<i>F</i>=70.03, <i>P</i><0.001).<b>Conclusion</b>  The neutralizing antibody test of the mice after immunization can be used to evaluate the potency of COID-19 mRNA vaccine in vivo.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[WU Xiaohong, ZHAO Danhua, SUO Yue, PENG Qinhua, WANG Hongyu, LIU Xinyu, LI Yuhua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Xiaohong, ZHAO Danhua, SUO Yue, PENG Qinhua, WANG Hongyu, LIU Xinyu, LI Yuhua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311009&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pollution analysis and health risk assessment of heavy metals in seventeen kinds of Chinese medicinal materials]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the pollution level and health risk of 5 kinds of heavy metals in 17 kinds of Chinese medicine materials, and to provide theoretical basis and data support for the development of rapid test methods for Chinese medicinal materials.<b>Methods</b>  The residual amount of heavy metals in17 kinds of Chinese medicinal materials was determined by ICP-MS. The over standard rate, single factor pollution index and Nemerow comprehensive pollution index were used to evaluate the degree of heavy metal pollution. Estimated daily intake (EDI), target hazard quotients (THQ) and total target hazard quotient (TTHQ) for health risk assessment. <b>Results</b>  According to the total over standard rate 17 kinds of Chinese medicinal materials were listed as follows：Zingiberis Rhizoma>Angelicae Pubescentis Radix>Bupleuri Radix>Asari Radix Et Rhizoma>Typhonii Rhizoma>Chuanxiong Rhizoma>Gastrodiae Rhizoma>Aquilariae Lignum Resinatum>Isatidis Radix>Chrysanthemi Flos>Amomum Villosum>Gardeniae Fructus>EuryAles Semen>Angelicae Dahuricae Radix>Lonicerae Japonicae Flos>Pogostemonis Herba>Atractylodis Rhizoma. Hg exceeded the standard most commonly, involving 14 kinds of medicinal materials, especially in Zingiberis Rhizoma, resulting in the single and comprehensive pollution index evaluation of Zingiberis Rhizoma were serious pollution level, the three pollution evaluation results were basically consistent. There were also multiple heavy metals exceeding the standard in 13 kinds of medicinal materials, among which Cd, Pb,Hg and As in Typhonii Rhizoma were exceeding the standard. The health assessment risk of 17 kinds of Chinese medicinal materials have no obvious health risk hazards. <b>Conclusion</b>  All the 17 kinds of Chinese medicinal materials have different degrees of excessive heavy metals, and the pollution phenomenon is widespread and the situation is severe. Although there is no obvious health harm, the aggravation of the cumulative risk of heavy metals is bound to affect the quality of Chinese medicinal materials and endanger human health. Therefore, attention should be paid to the pollution of heavy metals in Chinese medicinal materials, and favorable monitoring means should be adopted to control it.]]></description>
<pubDate>2023/12/11 10:46:55</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[YAN Yan<sup>1</sup>, QIN Bin<sup>1</sup>, LIANG Xue<sup>1</sup>, LIAN Shaomin<sup>1</sup>, WANG Bing<sup>1</sup>, WANG Bingzhi<sup>2</sup>, YAN Yiyong<sup>2</sup>, YIN Guo<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAN Yan<sup>1</sup>, QIN Bin<sup>1</sup>, LIANG Xue<sup>1</sup>, LIAN Shaomin<sup>1</sup>, WANG Bing<sup>1</sup>, WANG Bingzhi<sup>2</sup>, YAN Yiyong<sup>2</sup>, YIN Guo<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202311010&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Establishment and application of M-NIH for potency test of rabies vaccine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a modified NIH（M-NIH，single dilution method) to test the potency of rabies vaccine according to the 3R principles of animal testing, and to replace the traditional NIH method.<b>Methods</b>  Modified NIH (M-NIH)method was established by comparing the protection rate of mice between the single dilution of rabies vaccine and the eighth batch of national standard reference used in the potency test of rabies vaccine. And the repeatability, accuracy and applicability of M-NIH were verified. 52 batches of Rabies vaccines were compared by M-NIH method and NIH method, and a total of 247 batches of Rabies vaccines were verified by 9 laboratories. Kappa coefficient and Bowker test were used to evaluate the consistency of the two methods. The applicability of rabies vaccines from three manufactures was verified. A retrospective analysis in the past 4 years was made on the application of rabies vaccine lot release using M-NIH method after approval. <b>Results</b>  The verification results of 52 batches of rabies vaccine showed that the coincidence rate of the two methods was 92.3% (kappa=0.82, <i>P</i><0.01), and the coincidence rate of the 247 batches Rabies vaccines was 80.2% (kappa= 0.54, <i>P</i><0.01) in the extended verification.The coefficient of variation of M-NIH standard protection rate was 21.7% in intra-laboratory and 23.4% in inter-laboratory. The applicability verification results of three manufactures showed that the coincidence rate of M-NIH results and NIH results was 100%. In the past four years, a total of 820 batches of Rabies vaccines were tested, and the qualified rate was 93.8% by using M-NIH, M-NIH unqualified batches were finally determined by NIH method, and the qualified rate of rabies vaccine was 99.8%.<b>Conclusion</b>  M-NIH was established and approved to be used to test the potency of rabies vaccine. In the past 4 years, the efficiency of lot release of rabies vaccine was highly improved and the use of experiment mouse was greatly reduced by using M-NIH.]]></description>
<pubDate>2023/11/13 15:04:29</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[WU Xiaohong, CAO Shouchun, SHI Leitai, WANG Yunpeng, ZHAO Danhua, LI Jia, LI Yuhua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Xiaohong, CAO Shouchun, SHI Leitai, WANG Yunpeng, ZHAO Danhua, LI Jia, LI Yuhua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310008&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Content determination for 4 tocopherols in Seabuckthorn Seed Oil Soft Capsules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a HPLC method for determining contents of 4 tocopherols in Seabuckthorn Seed Oil Soft Capsules. <b>Methods</b>  HPLC analysis was performed on an Agilent Poroshell 120 PFP column (4.6 mm×250 mm, 4 μm) with the mobile phase of methanol-water (94∶6). The detection wavelength was 294 nm, the column temperature was 26 ℃, and the flow rate was 0.9 mL•min<sup>-1</sup>.<b> Results</b>  α-tocopherol, β-tocopherol, γ-tocopherol and δ-tocopherol showed good linear relationships in the ranges of 1.83-91.48, 1.86-93.09, 1.84-91.85, 1.77-88.70 μg•mL<sup>-1</sup>, respectively. The average recoveries was between 96.32%-98.45% with <i>RSD</i> between 0.48%-1.43%. <b>Conclusion</b>  The established method has good repeatability and specificity, and could be used to determine contents of 4 tocopherols in SSOSCs.]]></description>
<pubDate>2023/11/13 15:04:29</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[DONG Peng, WANG Xiaobing, LI Qiyan, WU Xiaoyun, YU Haiying, XIE Qiangsheng, GUO Dongxiao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DONG Peng, WANG Xiaobing, LI Qiyan, WU Xiaoyun, YU Haiying, XIE Qiangsheng, GUO Dongxiao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202310009&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparative analysis on main chemical constituents of <i>Dioscorea opposita</i> and adulterants]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a method for the content determination of total polysaccharides, total saponins, total flavonoids and total polyphenols in Chinese yam, and to compare the content difference of components with its adulterants to achieve the classification of <i>Dioscorea opposita</i> and adulterants. <b>Methods</b>  The 4 kinds of active components in 28 batches of Chinese yam and 15 batches of adulterants from different origins were determined by UV-visible spectrophotometer, and multivariate statistical analysis was conducted for classification. <b>Results</b>  All the four kinds of active components in Chinese yam and its adulterants were detected, and the total polysaccharide content was the highest, accounting for about 20% of the weight, and accounting for more than 90% of the four components. The classification of Yam and its adulterants could be realized based on the contents of four components, and the content of total polyphenols contributed the most to the classification. There was no significant quality difference among the main producing areas of Yam. <b>Conclusion</b>  The method established in this experiment is accurate and reliable. By determining the contents of 4 kinds of active components, the classification of Chinese yam and its adulterants can be realized, which provides scientific basis for quality control of Chinese yam based on functional substance and further development and utilization of Chinese yam planting resources.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[JIN Yibao<sup>1</sup>, TONG Yue<sup>2</sup>, CHEN Jiajia<sup>3</sup>, WANG Lu<sup>2</sup>, YIN Guo<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIN Yibao<sup>1</sup>, TONG Yue<sup>2</sup>, CHEN Jiajia<sup>3</sup>, WANG Lu<sup>2</sup>, YIN Guo<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403008&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effect of Human Immunoglobulin (pH4) for Intravenous Injection on complement system in vitro]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate whether Human Immunoglobulin for Intravenous Injection can activate the complement system by complement incubation experiments in vitro and to study the correlation between the complement system and anaphylactoid reactions during the administration of this product.<b>Methods</b>  Products from four enterprises were selected, and also were heated to obtain samples with elevated levels of polymers. After incubating the samples with human serum for 1 hour in vitro, the contents of the representative intermediate products of the complement system activation, and the terminal complex Sc5b-9 were determined by ELISA kits.<b>Results</b>  Compared with the normal saline control, the complement molecules C3a, C4a, C5a, Bb, and Sc5b-9 in the experimental group basically showed a downward trend; After heating the products, there was no significant increase in the complement molecules described above.<b>Conclusion</b>  Human Immunoglobulin for Intravenous Injection cannot cause anaphylactoid reactions by activating the complement system. On the contrary, it inhibited the complement system to a certain extent.]]></description>
<pubDate>2024/2/26 16:18:00</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[KE Bingbing, WANG Derong, LI Shixing, CHENG Menglan, GUO Jianghong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KE Bingbing, WANG Derong, LI Shixing, CHENG Menglan, GUO Jianghong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401008&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Determination of apremilast concentration in human plasma UHPLC-MS/MS and its bioequivalence study]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> A UHPLC-MS/MS method was developed for determination of apremilast in human plasma and the bioequivalence study. <b>Methods</b> Plasma sample was treated with methanol for protein precipitation while apremilast-d5 was used as internal standard (IS).  Separation was achieved on a Phenomenex Kinetex C<sub>18</sub> column (2.1×50 mm, 2.6 μm) by gradient elution at a flow rate of 0.45 mL·min<sup>-1</sup>, with acetonitrile (containing 0.1% of formic acid ) and water(containing 0.1% formic acid) as mobile phase. Detection was performed using electrospray ionization in positive ion multiple reaction monitoring (MRM) mode for three minutes.<b>Results</b> Calibration curves of apremilast were linear in the concentration range of 2~600 ng·mL<sup>-1</sup> (<i>r</i><sup>2</sup>=0.997 7), with precisions and accuracies were less than 15%. The 90 % confidence intervals of AUC<sub>0-t</sub>, AUC<sub>0-∞</sub> and Cmax of the test preparations of Apremilast tablets under fasting and postprandial conditions were within the ranges of 80.0 %~125.0 % of the corresponding parameters of the reference preparation.<b>Conclusion</b> The test preparation and reference preparation are bioequivalent.]]></description>
<pubDate>2024/2/26 16:18:00</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[ZHANG Xunjie<sup>1</sup>, HE Meilian<sup>1</sup>, HANG Baojian<sup>1</sup>, SHI Feng<sup>1</sup>, GONG Liping<sup>1</sup>, ZHANG Naibin<sup>1</sup>, XIAN Ruiqing<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xunjie<sup>1</sup>, HE Meilian<sup>1</sup>, HANG Baojian<sup>1</sup>, SHI Feng<sup>1</sup>, GONG Liping<sup>1</sup>, ZHANG Naibin<sup>1</sup>, XIAN Ruiqing<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202401009&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances on cellular membrane nanovesicles for tumor vaccines]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, breakthroughs have been made in tumor immunotherapy. Tumor vaccines can overcome immunosuppression by enhancing immunogenicity, thereby activating immunity to recognize and kill tumor cells, which is a promising immunotherapy modality. Biomimetic cellular membrane nanovesicles with the advantages of tumor specific targeting, prolonged half-life and immune activation effects have potential to flourish the design of tumor vaccines. In this review, we summarized the recent progresses of various cellular membrane nanovesicles in the application of tumor vaccines, discussed their characteristics, preparation, characterization and modification methods, and analyzed the challenges in clinical application.]]></description>
<pubDate>2025/3/12 11:34:39</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[ZHAO Jianing<sup>1,2,3</sup>, MA Tingting<sup>1,2,3</sup>, KUANG Xiaoqin<sup>1,2,3</sup>, HAO Mingyu<sup>1,2,3</sup>, LI Chunjiayu<sup>1,2,3</sup>, TU Jiasheng<sup>1,2,3</sup>, SUN Chunmeng<sup>1,2,3</sup>, WU Yanping<sup>1,4</sup>, CHEN Qian<sup>1,5</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Jianing<sup>1,2,3</sup>, MA Tingting<sup>1,2,3</sup>, KUANG Xiaoqin<sup>1,2,3</sup>, HAO Mingyu<sup>1,2,3</sup>, LI Chunjiayu<sup>1,2,3</sup>, TU Jiasheng<sup>1,2,3</sup>, SUN Chunmeng<sup>1,2,3</sup>, WU Yanping<sup>1,4</sup>, CHEN Qian<sup>1,5</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502010&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Determination of amino acid composition and peptide content in elcatonin by post-column derivatization cation-exchange chromatography]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To determine the amino acid composition and peptide content in elcatonin using amino acid analyzer and compare the results with those obtained from the pre-column derivatization high-performance liquid chromatography (HPLC) method. <b>Methods</b>  The chromatographic column was 2622SC-PH (4.6 mm×60 mm). The flow rate of pump A (pH series solution) was 0.4 mL•min<sup>-1</sup>, and the flow rate of pump B (ninhydrin solution) was 0.35 mL•min<sup>-1</sup>. The detection wavelengths were set at 440 nm (proline) and 570 nm (other amino acids). <b>Results</b>  The results showed that the linear relationship of the 14 amino acids was good, the repeatability RSD was 1.1%-2.5%, and the recovery was 98.0%-103.6%. The results were generally consistent with those obtained from the HPLC method. <b>Conclusion</b>  The amino acid analyzer method is simple and highly automated, and can be used to determine the amino acid composition and peptide content in elcatonin.]]></description>
<pubDate>2025/3/12 11:34:39</pubDate>
<category><![CDATA[Column of Key Laboratory of National Medical Products Administration]]></category>
<author><![CDATA[XUE Weili, LIANG Chaochao, SHI Feng, GONG Liping, ZHANG Dongmei, XIAN Ruiqing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XUE Weili, LIANG Chaochao, SHI Feng, GONG Liping, ZHANG Dongmei, XIAN Ruiqing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502011&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>